Schering-Plough Clarinex Launch Strategy Follows Nexium Model
Executive Summary
Schering-Plough's discounted pricing for the antihistamine Clarinex follows the model used by AstraZeneca to launch the anti-ulcer agent Nexium
You may also be interested in...
Schering-Plough Clarinex Has 12.3% New Rx Share As Of Feb. 25
Schering-Plough's Clarinex has garnered a 12.3% new prescription share as of the week of Feb. 25, Senior VP-Investor Relations & Corporate Communications Geraldine Foster said
Schering-Plough Clarinex Has 12.3% New Rx Share As Of Feb. 25
Schering-Plough's Clarinex has garnered a 12.3% new prescription share as of the week of Feb. 25, Senior VP-Investor Relations & Corporate Communications Geraldine Foster said
Allegra Growth Expected At 20% Annually; Generic Impact Possible In 2004
Aventis expects sales of its antihistamine Allegra (fexofenadine) to grow at a rate of about 20% annually, although generic competition could begin to have an impact beginning in 2004